824 related articles for article (PubMed ID: 17401425)
1. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
2. TP53 and liver carcinogenesis.
Staib F; Hussain SP; Hofseth LJ; Wang XW; Harris CC
Hum Mutat; 2003 Mar; 21(3):201-16. PubMed ID: 12619106
[TBL] [Abstract][Full Text] [Related]
3. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
Xue KX
Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
[TBL] [Abstract][Full Text] [Related]
4. Hepatocarcinogenesis: hepatitis viruses and altered tumor suppressor gene function.
Tabor E
Princess Takamatsu Symp; 1995; 25():151-61. PubMed ID: 8875620
[TBL] [Abstract][Full Text] [Related]
5. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; Caron de Fromentel C; Chemin IA; Hainaut PL
Carcinogenesis; 2010 Aug; 31(8):1475-82. PubMed ID: 20538734
[TBL] [Abstract][Full Text] [Related]
6. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.
Szymañska K; Chen JG; Cui Y; Gong YY; Turner PC; Villar S; Wild CP; Parkin DM; Hainaut P
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1638-43. PubMed ID: 19366907
[TBL] [Abstract][Full Text] [Related]
7. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
8. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand.
Kuang SY; Lekawanvijit S; Maneekarn N; Thongsawat S; Brodovicz K; Nelson K; Groopman JD
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):380-4. PubMed ID: 15734961
[TBL] [Abstract][Full Text] [Related]
10. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis.
Huo TI; Wang XW; Forgues M; Wu CG; Spillare EA; Giannini C; Brechot C; Harris CC
Oncogene; 2001 Jun; 20(28):3620-8. PubMed ID: 11439325
[TBL] [Abstract][Full Text] [Related]
12. Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States?
Hoque A; Patt YZ; Yoffe B; Groopman JD; Greenblatt MS; Zhang YJ; Santella RM
Nutr Cancer; 1999; 35(1):27-33. PubMed ID: 10624703
[TBL] [Abstract][Full Text] [Related]
13. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.
Stern MC; Umbach DM; Yu MC; London SJ; Zhang ZQ; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):617-25. PubMed ID: 11401911
[TBL] [Abstract][Full Text] [Related]
16. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.
Hsu IC; Metcalf RA; Sun T; Welsh JA; Wang NJ; Harris CC
Nature; 1991 Apr; 350(6317):427-8. PubMed ID: 1849234
[TBL] [Abstract][Full Text] [Related]
17. TP53 and hepatocellular carcinoma.
Puisieux A; Ozturk M
Pathol Biol (Paris); 1997 Dec; 45(10):864-70. PubMed ID: 9769950
[TBL] [Abstract][Full Text] [Related]
18. [Molecular aspects of hepatocellular carcinoma].
Moradpour D; Blum HE
Zentralbl Chir; 2000; 125(7):592-6. PubMed ID: 10960967
[TBL] [Abstract][Full Text] [Related]
19. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis.
Teramoto T; Satonaka K; Kitazawa S; Fujimori T; Hayashi K; Maeda S
Cancer Res; 1994 Jan; 54(1):231-5. PubMed ID: 8261444
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations.
Rashid A; Wang JS; Qian GS; Lu BX; Hamilton SR; Groopman JD
Br J Cancer; 1999 Apr; 80(1-2):59-66. PubMed ID: 10389978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
